Latest period
$117.21B
YoY change
-2.8%
5Y CAGR
+6.0%
Peak year (2023)
$137.21B
Latest annual
$121.39B
Total Liabilities history chart for Pfizer (PFE) from 1985 to 2025
Latest: $121.39B
Total Liabilities growth chart for Pfizer (PFE) from 1985 to 2025
Latest: -2.8%
Total Liabilities history table for Pfizer (PFE) from 1985 to 2025
| 2025 | $121.39B | -2.8% | −$3.51B | ||
| 2024 | $124.90B | -9.0% | −$12.31B | ||
| 2023 | $137.21B | +35.5% | +$35.92B | ||
| 2022 | $101.29B | -2.6% | −$2.73B | ||
| 2021 | $104.01B | +14.6% | +$13.26B | ||
| 2020 | $90.76B | -12.9% | −$13.39B | ||
| 2019 | $104.15B | +8.9% | +$8.48B | ||
| 2018 | $95.66B | -4.5% | −$4.48B | ||
| 2017 | $100.14B | -10.4% | −$11.63B | ||
| 2016 | $111.78B | +9.2% | +$9.39B | ||
| 2015 | $102.38B | +6.7% | +$6.44B | ||
| 2014 | $95.94B | +0.5% | +$463.00M | ||
| 2013 | $95.48B | -8.3% | −$8.64B | ||
| 2012 | $104.12B | -1.2% | −$1.26B | ||
| 2011 | $105.38B | -1.3% | −$1.37B | ||
| 2010 | $106.75B | -12.9% | −$15.75B | ||
| 2009 | $122.50B | +129.4% | +$69.09B | ||
| 2008 | $53.41B | +6.5% | +$3.26B | ||
| 2007 | $50.14B | +13.7% | +$6.03B | ||
| 2006 | $44.11B | -13.8% | −$7.09B | ||
| 2005 | $51.21B | -6.6% | −$3.59B | ||
| 2004 | $54.80B | +6.6% | +$3.40B | ||
| 2003 | $51.40B | +94.6% | +$24.99B | ||
| 2002 | $26.41B | +26.6% | +$5.55B | ||
| 2001 | $20.86B | +19.7% | +$3.43B | ||
| 2000 | $17.43B | +0.1% | +$12.00M | ||
| 1999 | $17.42B | +83.5% | +$7.93B | ||
| 1998 | $9.49B | +34.5% | +$2.43B | ||
| 1997 | $7.06B | -7.9% | −$605.00M | ||
| 1996 | $7.66B | +6.8% | +$486.90M | ||
| 1995 | $7.18B | +6.5% | +$440.30M | ||
| 1994 | $6.74B | +24.1% | +$1.31B | ||
| 1993 | $5.43B | +12.2% | +$589.50M | ||
| 1992 | $4.84B | +5.7% | +$262.70M | ||
| 1991 | $4.57B | +16.3% | +$642.60M | ||
| 1990 | $3.93B | +4.4% | +$166.40M | ||
| 1989 | $3.76B | +12.8% | +$428.40M | ||
| 1988 | $3.34B | +9.7% | +$296.30M | ||
| 1987 | $3.04B | +73.9% | +$1.29B | ||
| 1986 | $1.75B | +13.9% | +$212.80M | ||
| 1985 | $1.54B | — | — |
- 2025$121.39B-2.8%
- 2024$124.90B-9.0%
- 2023$137.21B+35.5%
- 2022$101.29B-2.6%
- 2021$104.01B+14.6%
- 2020$90.76B-12.9%
- 2019$104.15B+8.9%
- 2018$95.66B-4.5%
- 2017$100.14B-10.4%
- 2016$111.78B+9.2%
- 2015$102.38B+6.7%
- 2014$95.94B+0.5%
- 2013$95.48B-8.3%
- 2012$104.12B-1.2%
- 2011$105.38B-1.3%
- 2010$106.75B-12.9%
- 2009$122.50B+129.4%
- 2008$53.41B+6.5%
- 2007$50.14B+13.7%
- 2006$44.11B-13.8%
- 2005$51.21B-6.6%
- 2004$54.80B+6.6%
- 2003$51.40B+94.6%
- 2002$26.41B+26.6%
- 2001$20.86B+19.7%
- 2000$17.43B+0.1%
- 1999$17.42B+83.5%
- 1998$9.49B+34.5%
- 1997$7.06B-7.9%
- 1996$7.66B+6.8%
- 1995$7.18B+6.5%
- 1994$6.74B+24.1%
- 1993$5.43B+12.2%
- 1992$4.84B+5.7%
- 1991$4.57B+16.3%
- 1990$3.93B+4.4%
- 1989$3.76B+12.8%
- 1988$3.34B+9.7%
- 1987$3.04B+73.9%
- 1986$1.75B+13.9%
- 1985$1.54B—
Total Liabilities values are taken from Pfizer's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's latest reported total liabilities is $117.21B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Pfizer (PFE) total liabilities is $121.39B – edged down 2.8% year-over-year.
Pfizer total liabilities compound annual growth for the 2020–2025 (5 years) window is +6.0%, with mixed annual results across the window.
2023 marks the peak total liabilities at $137.21B, with the historical low of $1.54B recorded in 1985.
Pfizer Total Liabilities by Year
Pfizer Total Liabilities 2025: $121.39B
2025's total liabilities for Pfizer came in at $121.39B, edged down 2.8% below 2024.
Pfizer Total Liabilities 2024: $124.90B
Pfizer posted total liabilities of $124.90B in 2024, declined 9.0% below 2023.
Pfizer Total Liabilities 2023: $137.21B
In 2023, Pfizer reported total liabilities of $137.21B, surged 35.5% from 2022. This figure represents the highest annual value in the available history.
Pfizer Total Liabilities 2022: $101.29B
Pfizer total liabilities in 2022 was $101.29B, edged down 2.6% below 2021.
Pfizer Total Liabilities 2021: $104.01B
Pfizer total liabilities in 2021 was $104.01B.
See more financial history for Pfizer (PFE).
Sector peers by Total Liabilities
Healthcare peers of Pfizer (PFE), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation